13 Критики вакцин, подавляющих патогенность, разработали математические модели, указывающие на то, что такие вакцины могут привести даже к повышению патогенности, предотвращая “наказание” патогенных штаммов смертью хозяев. Но результаты реального применения таких вакцин, например противодифтерийной, оказались прямо противоположными. См.: Benoit Soubeyrand, Stanley Plotkin, “Microbial Evolution: Antitoxin Vaccines and Pathogen Virulence”, Nature 414 (2001), 751–756.
14 “Drug-Resistant Streptococcus pneumoniae Disease”, disease listing, National Center for Infectious Diseases /Division of Bacterial and Mycotic Diseases, October 6, 2005.
15 Moe Kyaw et al., “Effect of Introduction of the Pneumococcal Conjugate Vaccine on Drug-Resistant Streptococcus pneumoniae”, New England Journal of Medicine 354 (2006), 1455–1524.
16 Henry Shinefield et al., “Use of Staphylococcus aureus Conjugate Vaccine in Patients Receiving Hemodialysis”, New England Journal of Medicine 346 (2002) 491–496.
17 Yukiko Stranger-Jones et al., “Vaccine Assembly from Surface Proteins of Staphylococcus aureus” Proceedings of the National Academy of Sciences 103 (2006), 16942-16947.
18 Интервью, взятые автором у Юкико Стрейнджер-Джонс в ноябре – декабре 2006 г.
19 D. G. Brockstedt et al., “Killed but Metabolically Active Microbes: A New Vaccine Paradigm for Eliciting Effector T-cell Responses and Protective Immunity”, Nature Medicine 11 (2005), 853–860.
20 N. Porat et al., “Emergence of Penicillin-Nonsusceptible Streptococcus pneumoniae Clones Expressing Serotypes Not Present in the Antipneumococcal Conjugate Vaccine”, Journal of Infectious Diseases 190 (2004), 2154–2161.
21 Grace Lee et al., “Pertussis in Adolescents and Adults: Should We Vaccinate?” Pediatrics 115 (2005), 1675–1684.
22 Haemophilus Influenzae Type b (Hib) Vaccine: What You Need to Know (Atlanta: Centers for Disease Control, 2006).
23 Heikki Peltola, “Worldwide Haemophilus influenzae Type b Disease at the Beginning of the 21st Century”, Clinical Microbiology Reviews 13 (2000), 302–317.
24 Elie Metchnikoff, The Prolongation of Life (New York: G. P. Putnam’s Sons, 1908).
25 Sherwood Gorbach, “The Discovery of Lactobacillus GG” Nutrition Today 31 (1996), 2S – 4S.
26 H. L. DuPont, “Prevention of Diarrhea by the Probiotic Lactobacillus GG” Journal ofPediatrics 134 (1999), 1–2; T. Arvola et al., “Prophylactic Lactobacillus GG Reduces Antibiotic-Associated Diarrhea in Children with Respiratory Infections: A Randomized Study”, Pediatrics 104 (1999), e64; E. Hilton et al., “Efficacy of Lactobacillus GG as a Diarrheal Preventive in Travelers”, Journal of Travel Medicine 4 (1997), 41–43; J. A. Billier et al., “Treatment of Recurrent Clostridium difficile Colitis with Lactobacillus GG” Pediatric Gastroenterology and Nutrition 21 (1995), 224–226.
27 Andrew Bruce et al., “Recurrent Urethritis in Women”, Canadian Medical Association Journal 108 (1973), 973–976; Andrew Bruce et al., “The Significance of Perineal Pathogens in Women”, Journal of Urology 112 (1974), 808–810.
28 J. D. Sobel, “Is There a Protective Role for Vaginal Flora?” Current Infectious Disease Reports 1 (1999), 379–383; Marie Pirotta et al., “Effect of Lactobacillus in Preventing Post-antibiotic Vulvovaginal Candidiasis: A Randomised Controlled Trial”, British Medical Journal 329 (2004), 548–551; T. Kontiokari et al., “Randomized Trial of Cranberry-Lingonberry Juice and Lactobacillus GG Drink for the Prevention of Urinary Tract Infections in Women”, British Medical Journal 322 (2001), 1571–1575.
29 Gregor Reid, “In Vitro Testing of Lactobacillus acidophilus NCFM as a Possible Probiotic for the Urogenital Tract”, International Dairy Journal 10 (2000), 415–419.
